Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOVE-UC vedolizumab early versus late use in ulcerative colitis
2014-005443-40Phase 4Completed
- Sponsor
- Academic Medical Center
- Start
- Jan 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of vedolizumab in autoimmune colitis (2 cohorts), sponsored by Academic Medical Center. Primary endpoints: Clinical and endoscopic remission at Week 26 and Clinical and endoscopic remission at Week 52-54. Started Jan 2015; status: completed.
02
Drugs
vedolizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2014-005443-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005443-40.